Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin plus methylprednisolone for acute spinal cord injury
ACTRN12609000602224Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Sep 2006
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of erythropoietin and methylprednisolone sodium succinate in spinal cord injury (SCI) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Neurologic examination for determination of American Spinal Injury Association (ASIA) scale. Started Sep 2006; status: completed.
02
Drugs
erythropoietinmethylprednisolone sodium succinate
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on ACTRN12609000602224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000602224.